PMID- 19219529
OWN - NLM
STAT- MEDLINE
DCOM- 20090402
LR  - 20240321
IS  - 1661-4917 (Electronic)
IS  - 0004-069X (Print)
IS  - 0004-069X (Linking)
VI  - 57
IP  - 1
DP  - 2009 Jan-Feb
TI  - Biological activity of dendritic cells generated from cord blood CD34+ 
      hematopoietic progenitors in IL-7- and IL-13-conditioned cultures.
PG  - 67-74
LID - 10.1007/s00005-009-0005-1 [doi]
AB  - INTRODUCTION: Dendritic cells (DCs) are required for initiation of the immune 
      response and may therefore be used for the production of cancer vaccines. As 
      mature DCs (mDCs) are the most potent antigen-presenting cells, there is 
      increasing interest in generating them ex vivo. The present study was designed to 
      obtain mDCs from CD34+ hematopoietic progenitors by culturing them in different 
      media. MATERIALS AND METHODS: Cord blood CD34+ hematopoietic progenitors were 
      expanded for 7 days in FST medium containing fms-related tyrosine kinase 3 ligand 
      (Flt3-L), stem cell factor (SCF), and thrombopoietin (TPO). Then the cells were 
      divided into three parts and cultured for 21 days in different media: FST medium 
      or FST enriched in interleukin (IL)-3 (FST3 medium) or supplemented with IL-7 and 
      IL-13 (FST713 medium). At the end of culture part of the cells was harvested, 
      counted, and analyzed while the other part was matured with proinflammatory 
      cytokines for 2 days. The cells' phenotypes, ability to induce proliferation of 
      allogeneic lymphocytes in the mixed lymphocyte reaction (allo-MLR), chemotaxis, 
      phagocytosis, and O2(-) production were determined. RESULTS: The average fold 
      increase of DCs at the end of culture in FST medium was 127, in FST3 1043, and in 
      FST713 71. In comparison with the other media, FST713 medium supported the 
      generation of mDCs that were characterized by higher expression of CD83, 
      costimulatory molecules, and HLA-DR, enhanced ability to induce allo-MLR and 
      migration to -macrophage inflammatory protein (MIP) 3beta poor phagocytosis, and 
      O2(-) production. CONCLUSIONS: This study indicates that FST713 medium allows the 
      generation of limited numbers of more mature DCs, while FST3 medium leads to the 
      production of immature DCs in high numbers.
FAU - Mytar, Bozenna
AU  - Mytar B
AD  - Department of Clinical Immunology, Polish-American Institute of Pediatrics, 
      Jagiellonian University Medical College, Cracow, Poland.
FAU - Stec, Malgorzata
AU  - Stec M
FAU - Weglarczyk, Kazimierz
AU  - Weglarczyk K
FAU - Zembala, Marek
AU  - Zembala M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090214
PL  - Poland
TA  - Arch Immunol Ther Exp (Warsz)
JT  - Archivum immunologiae et therapiae experimentalis
JID - 0114365
RN  - 0 (CCR7 protein, human)
RN  - 0 (Chemokine CCL19)
RN  - 0 (Culture Media)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interleukin-3)
RN  - 0 (Interleukin-7)
RN  - 0 (Membrane Proteins)
RN  - 0 (Receptors, CCR7)
RN  - 0 (Stem Cell Factor)
RN  - 0 (flt3 ligand protein)
RN  - 11062-77-4 (Superoxides)
RN  - 9014-42-0 (Thrombopoietin)
SB  - IM
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured/drug effects
MH  - Chemokine CCL19/pharmacology
MH  - Chemotaxis/drug effects
MH  - Culture Media/pharmacology
MH  - Dendritic Cells/*immunology
MH  - Fetal Blood/*cytology
MH  - HLA-DR Antigens/biosynthesis
MH  - Hematopoietic Stem Cells/*cytology/drug effects
MH  - Humans
MH  - Immunophenotyping
MH  - Infant, Newborn
MH  - Interleukin-3/*pharmacology
MH  - Interleukin-7/*pharmacology
MH  - Lymphocyte Activation
MH  - Lymphocyte Culture Test, Mixed
MH  - Membrane Proteins/pharmacology
MH  - Phagocytosis
MH  - Receptors, CCR7/biosynthesis/genetics
MH  - Stem Cell Factor/pharmacology
MH  - Superoxides/metabolism
MH  - Thrombopoietin/pharmacology
PMC - PMC2771131
EDAT- 2009/02/17 09:00
MHDA- 2009/04/03 09:00
PMCR- 2009/11/01
CRDT- 2009/02/17 09:00
PHST- 2008/02/11 00:00 [received]
PHST- 2008/12/19 00:00 [accepted]
PHST- 2009/02/17 09:00 [entrez]
PHST- 2009/02/17 09:00 [pubmed]
PHST- 2009/04/03 09:00 [medline]
PHST- 2009/11/01 00:00 [pmc-release]
AID - 5 [pii]
AID - 10.1007/s00005-009-0005-1 [doi]
PST - ppublish
SO  - Arch Immunol Ther Exp (Warsz). 2009 Jan-Feb;57(1):67-74. doi: 
      10.1007/s00005-009-0005-1. Epub 2009 Feb 14.